Cargando…
Management of Drug Toxicity in Mycobacterium avium Complex Pulmonary Disease: An Expert Panel Survey
Adverse events are frequent in nontuberculous mycobacteria pulmonary disease treatment, but evidence to support their management is scarce. An expert panel survey on management of adverse events shows consistent opinions on management of hepatoxicity, ocular toxicity, ototoxicity, tinnitus, and gast...
Autores principales: | van Ingen, Jakko, Aliberti, Stefano, Andrejak, Claire, Chalmers, James D, Codecasa, Luigi R, Daley, Charles L, Hasegawa, Naoki, Griffith, David E, Hoefsloot, Wouter, Huitt, Gwen, Jarand, Julie, Jhun, Byung Woo, Loebinger, Michael R, Marras, Theodore K, Morimoto, Kozo, Polverino, Eva, Ringshausen, Felix C, Santin, Miguel, Thomson, Rachel, Wagner, Dirk, Wallace, Richard J, Winthrop, Kevin L, Yim, Jae-Joon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8491833/ https://www.ncbi.nlm.nih.gov/pubmed/32910814 http://dx.doi.org/10.1093/cid/ciaa1361 |
Ejemplares similares
-
Amikacin Liposome Inhalation Suspension for Mycobacterium avium Complex Lung Disease: A 12-Month Open-Label Extension Clinical Trial
por: Winthrop, Kevin L., et al.
Publicado: (2021) -
The role of rifampicin within the treatment of Mycobacterium avium pulmonary disease
por: Schildkraut, Jodie A., et al.
Publicado: (2023) -
Subtle immunodeficiencies in nodular–bronchiectatic Mycobacterium avium complex lung disease
por: Bruno, Mariolina, et al.
Publicado: (2020) -
Treatment of severe Mycobacterium avium complex pulmonary disease with adjunctive amikacin and clofazimine versus standard regimen alone: a retrospective study
por: Zweijpfenning, Sanne M.H., et al.
Publicado: (2021) -
Mycobacterium avium Complex: Addressing Gaps in Diagnosis and Management
por: Daley, Charles L, et al.
Publicado: (2020)